You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

CLINICAL TRIALS PROFILE FOR OFATUMUMAB

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for ofatumumab

Subscribe to access the full database, or Sign Up
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00349349 ↗	HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Failing Fludarabine and Alemtuzumab	Completed	GlaxoSmithKline	Phase 2	2006-06-01	The purpose of this study is to determine whether HuMax-CD20 (ofatumumab) is effective in the treatment of patients failing both fludarabine and alemtuzumab.
NCT00394836 ↗	HuMax-CD20 i(Ofatumumab) n Follicular Lymphoma (FL) Patients Refractory to Rituximab	Completed	GlaxoSmithKline	Phase 2	2007-05-01	A Single-Arm, International, Multi-Center Trial of HuMax-CD20 (Ofatumumab), a Fully Human Monoclonal Anti-CD20 Antibody, in Patients With Follicular Lymphoma Who Are Refractory to Rituximab as Monotherapy or in Combination With Chemotherapy
NCT00410163 ↗	Ofatumumab With Fludarabine and Cyclophosphamide in B-CLL Patients	Completed	GlaxoSmithKline	Phase 2	2007-01-01	To investigate the safety and efficacy of two dose regimes of ofatumumab in combination with chemotherapy in previously untreated patients with B-CLL
NCT00494780 ↗	Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide,Doxorubicin, Vincristine, Predisolone) in Follicular Lymphoma (FL) Patients	Completed	GlaxoSmithKline	Phase 2	2007-06-01	To investigate the efficacy in two dose regimens of ofatumumab in combination with CHOP (cyclophosphamide,doxorubicin, vincristine,prednisolone) in previously untreated patients with Follicular Lymphoma (FL)
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for ofatumumab

Condition Name

Chart
Table

Condition Name for ofatumumab
Intervention	Trials
Chronic Lymphocytic Leukemia	25
Small Lymphocytic Lymphoma	13
Leukaemia, Lymphocytic, Chronic	10
Chronic Lymphocytic Leukemia (CLL)	6
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for ofatumumab
Intervention	Trials
Leukemia, Lymphoid	61
Leukemia	61
Leukemia, Lymphocytic, Chronic, B-Cell	57
Lymphoma	51
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for ofatumumab

Trials by Country

Map
Table

Trials by Country for ofatumumab
Location	Trials
United States	338
Italy	82
Germany	61
United Kingdom	53
Spain	34
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for ofatumumab
Location	Trials
Florida	27
Texas	23
California	20
Tennessee	18
New York	15
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for ofatumumab

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for ofatumumab
Clinical Trial Phase	Trials
Phase 4	6
Phase 3	20
Phase 2	78
[disabled in preview]	7
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for ofatumumab
Clinical Trial Phase	Trials
Completed	64
Terminated	20
Active, not recruiting	15
[disabled in preview]	11
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for ofatumumab

Sponsor Name

Chart
Table

Sponsor Name for ofatumumab
Sponsor	Trials
GlaxoSmithKline	49
Novartis Pharmaceuticals	21
Novartis	16
[disabled in preview]	12
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for ofatumumab
Sponsor	Trials
Industry	124
Other	97
NIH	14
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.